90
Participants
Start Date
April 19, 2012
Primary Completion Date
August 18, 2014
Study Completion Date
June 18, 2015
Liposomal amikacin for inhalation (LAI)
"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension."
placebo
"* Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
Birmingham
Stanford
Denver
Washington D.C.
Gainesville
Miami
Tampa
Kansas City
Bethesda
Rochester
New York
Chapel Hill
Cleveland
Portland
Philadelphia
Charleston
Tyler
Milwaukee
Hamilton
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Insmed Incorporated
INDUSTRY